Articles tagged with Anticoagulants
The use of anticoagulants, antiplatelet agents, and thrombolytics in acute coronary syndromes (ACS) increases the risk of bleeding, which has emerged as a major contributor to poor outcomes. Careful selection of drugs and measures to prevent gastrointestinal bleeding can help mitigate this risk.
A five-year clinical trial has shown that computer-assisted dosage of blood thinning drugs is at least as safe and reliable as those provided by expert medical professionals. The study involved over 13,000 patients and nearly 400,000 INR tests, confirming the effectiveness of computer-assisted dosage.
A new review of 28,000 patients undergoing joint replacement surgery found that potent anticoagulants may actually lead to more deaths. The authors argue that these drugs have significant side effects and do not prevent pulmonary embolism effectively.
A study published in JAMA found that high-dose tirofiban had similar outcomes to abciximab in reducing ST-segment elevation after angioplasty. Additionally, sirolimus-releasing stents reduced major adverse cardiac events by half compared to uncoated stents.
The HORIZONS AMI trial enrolled over 3600 patients with a heart attack, examining the safety and effectiveness of stents and anticoagulants in heart attack patients undergoing angioplasty. The study aims to determine whether using bivalirudin provides the same benefit as standard anticoagulant therapy without causing excess bleeding.
The UNC School of Pharmacy team has developed a new synthetic form of heparin called Recomparin, which is less complex and easier to produce than previous forms. This reduction in structural complexity is expected to lower the risk of uncontrolled bleeding while maintaining the drug's anticoagulant properties.
Researchers developed a genetic dosing model to predict optimal warfarin dose for patients undergoing orthopedic surgery. The model combines genotype information with clinical factors to estimate therapeutic dosage.
A study of 40,171 patients found a 4-6 fold increase in gastrointestinal bleeding when warfarin was used with antiplatelet agents. Physicians should be aware of these risks to better assess their patients' therapeutic risk-benefit profiles.
A new drug-antidote combination has been shown to be safe in its first clinical trial, offering a potential 'on-off' switch for controlled anticoagulation. The treatment targets human coagulation factor IXa and rapidly reverses the anticoagulant's effects.
A new laboratory test can help determine whether patients with a history of venous blood clot are at low risk of developing another blood clot. Patients with low thrombin generation levels, measured by the commercially available test, have a low risk of recurrence, with an estimated 7% likelihood after 4 years.
Patients with atrial fibrillation have a five times higher stroke risk than those without the condition. Warfarin has been shown to reduce stroke risk by a significant margin, outperforming alternative treatments like aspirin and clopidogrel in reducing stroke rates by nearly two-thirds.
Researchers discovered genetic variations in the VKORC1 gene that affect warfarin dosing, allowing for more precise patient treatment. The study, supported by the NIH Pharmacogenetics Research Network, may enable doctors to set ideal doses quickly and precisely.
A new analysis found that heavy alcohol drinking was associated with an increased risk of ischemic stroke in men. Moderate drinking of red wine, on the other hand, was linked to a lower risk of stroke compared to other forms of alcohol consumption.
The final pooled analysis of SPORTIF III and V1,2 confirms ximelagatran's effectiveness in preventing strokes in patients with atrial fibrillation. Ximelagatran offers a safer alternative to warfarin without coagulation monitoring or dose titration, reducing the risk of stroke by 62%.
Exanta shows comparable efficacy to warfarin in preventing stroke in patients with atrial fibrillation, with the added benefit of no dose titration or routine coagulation monitoring. The THRIVE programme also highlights Exanta's promise in treating venous thromboembolism.
A randomized trial of 17,000 patients from 46 countries shows that bivalirudin reduces the risk of recurrent heart attack by 30% compared to heparin. The study also found no significant increase in severe bleeding or intracerebral bleeding in patients given bivalirudin.
Exanta demonstrated improved safety and tolerability compared to warfarin in treating patients with medium to high risk for stroke and systemic embolism. The phase III SPORTIF programme enrolled over 6,200 patients and showed promising results. Exanta is being investigated as a simpler alternative to warfarin treatment.
A large clinical trial found that widely used therapy with LMW heparinoids after a stroke has little effect on producing good outcomes or preventing second strokes. However, the therapy may be beneficial for patients with large artery atherosclerosis.